B. Lämmle

发表

This article has been cited by other articles

J. Moake, A. Bernardo, K. Fujikawa, 2003 .

Protein C replacement in severe meningococcemia: rationale and clinical experience.

B. Lämmle, L. Alberio, C. Esmon, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Congenital thrombotic thrombocytopenic purpura caused by new compound heterozygous mutations of the ADAMTS13 gene

B. Lämmle, J. K. Kremer Hovinga, O. Nielsen, 2014, European journal of haematology.

The von Willebrand Factor-Cleaving Protease (ADAMTS-13) and the Diagnosis of Thrombotic Thrombocytopenic Purpura (TTP)

B. Lämmle, J. K. Kremer Hovinga, J. Studt, 2003, Pathophysiology of Haemostasis and Thrombosis.

Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13).

B. Lämmle, H. Schwarz, F. Scheiflinger, 2002, Blood.

Partial amino acid sequence of purified von Willebrand factor-cleaving protease.

B. Lämmle, H. Gerritsen, M. Furlan, 2001, Blood.

Invited commentary to: ADAMTS13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19 by Tiffany Pascreau et al. Letter to the Editors-in-Chief, Thrombosis Research

B. Lämmle, H. Rossmann, 2021, Thrombosis Research.

Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis

B. Lämmle, P. Reitsma, H. Crijns, 2020, Thrombosis and Haemostasis.

Usefulness of the D‐dimer/fibrinogen ratio to predict deep venous thrombosis

B. Lämmle, W. Korte, W. Wuillemin, 2005, Journal of thrombosis and haemostasis : JTH.

Rapid D-dimer testing and pre-test clinical probability in the exclusion of deep venous thrombosis in symptomatic outpatients

B. Lämmle, I. Baumgartner, W. Korte, 2001, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Design and establishment of a biobank in a multicenter prospective cohort study of elderly patients with venous thromboembolism (SWITCO65+)

B. Lämmle, D. Aujesky, S. Trelle, 2013, Journal of Thrombosis and Thrombolysis.

Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature: only a part of the story. Reply to E. J. Favaloro

B. Lämmle, L. Alberio, Manuel Zürcher, 2008, Thrombosis and Haemostasis.

Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome, 1996 to 2011 (CME)

S. Vesely, J. George, B. Lämmle, 2012, Transfusion.

Polypharmacy is Associated with an Increased Risk of Bleeding in Elderly Patients with Venous Thromboembolism

B. Lämmle, M. Aschwanden, J. Cornuz, 2015, Journal of General Internal Medicine.

von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

B. Lämmle, G. Remuzzi, P. Kyrle, 1998, The New England journal of medicine.

Plasma protein C inhibitor is elevated in survivors of myocardial infarction.

B. Lämmle, B. Binder, M. Griffiths, 1997, Arteriosclerosis, thrombosis, and vascular biology.

Coagulation factors II, V, VII, and X, prothrombin gene 20210G-->A transition, and factor V Leiden in coronary artery disease: high factor V clotting activity is an independent risk factor for myocardial infarction.

B. Lämmle, B. Binder, H. Watzke, 1999, Arteriosclerosis, thrombosis, and vascular biology.

Annual Incidence and Severity of Acute Episodes in Hereditary Thrombotic Thrombocytopenic Purpura.

J. George, B. Lämmle, Z. Prohászka, 2021, Blood.

Polyendocrine deficiency syndrome. Occurrence in a patient with depressed IgA titers receiving phenytoin.

B. Lämmle, H. Haas, U. Schwarz, 1980, Archives of internal medicine.

Evaluation of a Platelet Function Analyser (PFA-100) in patients with a bleeding tendency.

B. Lämmle, S. Zeerleder, W. Wuillemin, 2002, Swiss medical weekly.

Standardized Management Protocol in Severe Postpartum Hemorrhage: A Single-Center Study

B. Lämmle, L. Alberio, B. Eberle, 2018, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Low-dose recombinant factor VIIa for massive bleeding: a single centre observational cohort study with 73 patients.

B. Lämmle, L. Alberio, A. Hirt, 2011, Swiss medical weekly.

Coagulation factor XII Locarno: the functional defect is caused by the amino acid substitution Arg 353-->Pro leading to loss of a kallikrein cleavage site.

B. Lämmle, H. Stricker, W. Wuillemin, 1994, Blood.

Enhanced specificity of immunoblotting using radiolabeled antigen overlay: studies of blood coagulation factor XII and prekallikrein in plasma.

B. Lämmle, J. Griffin, M. Berrettini, 1986, Analytical biochemistry.

ADAMTS13 activity, von Willebrand factor, factor VIII and D-dimers in COVID-19 inpatients

B. Lämmle, R. Escher, N. Breakey, 2020, Thrombosis Research.

Association of two silent polymorphisms of platelet glycoprotein la/lla receptor with risk of myocardial infarction: a case-control study

B. Lämmle, J. Beer, S. Liechti‐Gallati, 1999, The Lancet.

Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B.

B. Lämmle, P. Vock, A. Oláh, 1996, British journal of rheumatology.

Increased fibrin monomer plasma concentration in stable coronary artery disease in patients without oral anticoagulation.

B. Lämmle, W. Wuillemin, C. Caliezi, 2001, Atherosclerosis.

Formation of the fibrin clot: the balance of procoagulant and inhibitory factors.

B. Lämmle, J. Griffin, 1985, Clinics in haematology.

Severe COVID-19 infection associated with endothelial activation

B. Lämmle, R. Escher, N. Breakey, 2020, Thrombosis Research.

Mycobacterium genavense infection in a patient with long‐standing chronic lymphocytic leukaemia

B. Lämmle, T. Bodmer, S. Zimmerli, 2000, Journal of internal medicine.

Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management

B. Lämmle, S. Cataland, S. Sukumar, 2021, Journal of clinical medicine.

The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017

S. Vesely, J. George, B. Lämmle, 2019, Haematologica.

Assay of von Willebrand Factor (vWF)-cleaving Protease Based on Decreased Collagen Binding Affinity of Degraded vWF

B. Lämmle, H. Schwarz, P. Turecek, 1999, Thrombosis and Haemostasis.

Hyperbilirubinemia interferes with ADAMTS‐13 activity measurement by FRETS‐VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies

B. Lämmle, J. K. Kremer Hovinga, S. Meyer, 2007, Journal of thrombosis and haemostasis : JTH.

Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura.

B. Lämmle, M. Furlan, R. Robles, 1998, Blood.

Recovery and Half-Life of von Willebrand Factor-Cleaving Protease after Plasma Therapy in Patients with Thrombotic Thrombocytopenic Purpura

B. Lämmle, M. Furlan, R. Robles, 1999, Thrombosis and Haemostasis.

Accuracy of d‐dimer/fibrinogen ratio to predict pulmonary embolism: a prospective diagnostic study

B. Lämmle, N. Kucher, D. Wallmann, 2003, Journal of thrombosis and haemostasis : JTH.

Initial experience from a double‐blind, placebo‐controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura

B. Lämmle, P. Mannucci, B. Jilma, 2012, American journal of hematology.

Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura.

B. Lämmle, P. Mannucci, F. Dorner, 2004, Blood.

ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor‐cleaving protease activity by recombinant human ADAMTS13

B. Lämmle, F. Scheiflinger, B. Plaimauer, 2003, British journal of haematology.

Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry

J. George, B. Lämmle, P. Knöbl, 2013, Hämostaseologie.

Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS‐13)

B. Lämmle, S. Ferrari, P. Mannucci, 2008, Journal of thrombosis and haemostasis : JTH.

Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.

B. Lämmle, M. Furlan, R. Robles, 1996, Blood.

Deficient Activity of von Willebrand Factor–Cleaving Protease in Chronic Relapsing Thrombotic Thrombocytopenic Purpura

B. Lämmle, M. Furlan, R. Robles, 1997 .

Association between thyroid dysfunction and venous thromboembolism in the elderly: a prospective cohort study

B. Lämmle, M. Aschwanden, J. Cornuz, 2016, Journal of thrombosis and haemostasis : JTH.

Sporadic bloody diarrhoea‐associated thrombotic thrombocytopenic purpura‐haemolytic uraemic syndrome: an adult and paediatric comparison

S. Vesely, J. George, B. Lämmle, 2008, British journal of haematology.

Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism

B. Lämmle, M. Aschwanden, J. Cornuz, 2013, Journal of thrombosis and haemostasis : JTH.

Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients.

B. Lämmle, L. Alberio, M. Tschudi, 2009, Blood.

Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia.

B. Lämmle, L. Alberio, B. M. Taleghani, 2003, The American journal of medicine.

Anticoagulation Management Practices and Outcomes in Elderly Patients with Acute Venous Thromboembolism: A Clinical Research Study

B. Lämmle, M. Aschwanden, N. Rodondi, 2016, PloS one.

Monitoring of heparin treatment. Comparison of thrombin time, activated partial thromboplastin time, and plasma heparin concentration, and analysis of the behavior of antithrombin III.

B. Lämmle, H. Bounameaux, R. Eichlisberger, 1980, American journal of clinical pathology.

antibodies kininogen in human plasma by immunoblotting with monoclonal Detection of in vitro and in vivo cleavage of high molecular weight

B. Lämmle, J. Curd, B. Zuraw, 2011 .

Hemostatic and fibrinolytic parameters in survivors of myocardial infarction: a low plasma level of plasmin–α2-antiplasmin complex is an independent predictor of coronary re-events

B. Lämmle, B. Binder, W. Wuillemin, 2001, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

No Evidence for Classic Thrombotic Microangiopathy in COVID-19

B. Lämmle, P. Galle, K. Lackner, 2021, Journal of clinical medicine.

Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab

B. Lämmle, P. Wild, K. Lackner, 2018, Thrombosis and Haemostasis.

Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency

B. Lämmle, S. Honda, T. Miyata, 2016, International Journal of Hematology.

Gut microbiota regulate hepatic von Willebrand factor synthesis and arterial thrombus formation via Toll-like receptor-2.

B. Lämmle, U. Walter, J. Baines, 2017, Blood.

Fibrinogen Bern I: substitution gamma 337 Asn-->Lys is responsible for defective fibrin monomer polymerization.

B. Lämmle, M. Furlan, G. Heinemann, 1993, Blood.

Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies.

B. Lämmle, D. Wagner, T. Fuchs, 2012, Blood.

von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models.

B. Lämmle, A. Chauhan, D. Wagner, 2011, Blood.

Performance of a New Fibrin Monomer Assay to Exclude Deep Vein Thrombosis in Symptomatic Outpatients

B. Lämmle, I. Baumgartner, W. Wuillemin, 1999, Thrombosis and Haemostasis.

Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems

B. Lämmle, L. Alberio, L. Chilver-Stainer, 2003, Thrombosis and Haemostasis.

Tryptase from human mast cells does not activate purified human Hageman Factor

B. Lämmle, J. Griffin, L. Schwartz, 1988, Clinical allergy.

The Oklahoma Thrombotic Thrombocytopenic Purpura–Hemolytic Uremic Syndrome Registry: the Swiss connection

S. Vesely, J. George, B. Lämmle, 2008, European journal of haematology.

Dural puncture and activated protein C resistance: risk factors for cerebral venous sinus thrombosis

B. Lämmle, C. Ozdoba, M. Sturzenegger, 1997, Journal of neurology, neurosurgery, and psychiatry.

Treatment of thrombotic thrombocytopenic purpura

B. Lämmle, J. K. Kremer Hovinga, S. Fontana, 1983, Vox sanguinis.

Agreement of D-dimer results measured by a rapid ELISA (VIDAS) before and after storage during 24h or transportation of the original whole blood samples.

B. Lämmle, P. de Moerloose, G. Reber, 2000, Thrombosis and haemostasis.

Phenprocoumon-induced hepatitis delaying precise diagnosis in a thrombophilic patient with activated protein C resistance due to factor V R506Q mutation.

B. Lämmle, W. Wuillemin, R. Zenhäusern, 1997, The American journal of medicine.

Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins.

B. Lämmle, J. K. Kremer Hovinga, C. Dahinden, 2004, Blood.

von Willebrand factor and factor VIII in renal transplant recipients under immunosuppression with cyclosporine and steroids. Sequential measurements over 4 months in 17 patients.

B. Lämmle, M. Mihatsch, M. Oberholzer, 1990, Clinical nephrology.

Do Factor V Leiden and Prothrombin G20210A Mutations Predict Recurrent Venous Thromboembolism in Older Patients?

B. Lämmle, L. Alberio, N. Rodondi, 2017, The American journal of medicine.

[Autoimmune polyendocrinopathy with IGA deficiency].

B. Lämmle, H. Haas, U. Schwarz, 1978, Schweizerische medizinische Wochenschrift.

Plasma DNA is Elevated in Patients with Deep Vein Thrombosis.

B. Lämmle, D. Wagner, T. Wakefield, 2013, Journal of vascular surgery. Venous and lymphatic disorders.

Effect of low-molecular weight dextran sulfate on coagulation and platelet function tests.

B. Lämmle, S. Zeerleder, W. Wuillemin, 2002, Thrombosis research.

Thrombotic thrombocytopenic purpura

B. Lämmle, L. Alberio, J. K. Kremer Hovinga, 2005, The hematology journal : the official journal of the European Haematology Association.

Platelets: thrombotic thrombocytopenic purpura.

J. George, B. Lämmle, J. Sadler, 2002, Hematology. American Society of Hematology. Education Program.

Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.

B. Lämmle, M. Furlan, 2001, Best practice & research. Clinical haematology.

Immunoblotting studies of the molecular forms of protein C in plasma.

B. Lämmle, J. Griffin, H. Schwarz, 1988, Thrombosis research.

Is factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS 13 deficiency?

B. Lämmle, J. K. Kremer Hovinga, J. Studt, 2005, Thrombosis and haemostasis.

Venous thrombosis after Caesarean section in a young woman with homozygous APC resistance and type I protein S deficiency

B. Lämmle, A. Tobler, M. Furlan, 1997, European journal of haematology.

Depression and cognitive deficits as long‐term consequences of thrombotic thrombocytopenic purpura

B. Lämmle, M. Beutel, K. Lackner, 2017, Transfusion.

Low molecular weight heparin‐induced thrombocytopenia and skin necrosis distant from injection sites

B. Lämmle, M. Furlan, F. D. Biasiutti, 1994, European journal of haematology.

The incidence of thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS‐13 deficiency

S. Vesely, J. George, B. Lämmle, 2005, Journal of thrombosis and haemostasis : JTH.

Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpura.

S. Vesely, J. George, B. Lämmle, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Komplexe Gerinnungsstörungen

B. Lämmle, W. Rath, J. K. Kremer Hovinga, 2010, Hämostaseologie.

ADAMTS13 gene variants and function in women with preeclampsia: a population- based nested case- control study from the HUNT Study.

B. Lämmle, P. Romundstad, A. Waage, 2015, Thrombosis research.

Animal models of thrombotic thrombocytopenic purpura: the tales from zebrafish

B. Lämmle, P. Coppo, 2020, Haematologica.

Thrombotic microangiopathy: Caplacizumab accelerates resolution of acute acquired TTP

B. Lämmle, 2016, Nature Reviews Nephrology.

History of Thrombotic Thrombocytopenic Purpura and the von Willebrand Factor–Cleaving Protease, ADAMTS13

B. Lämmle, C. Auer, 2015 .

Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura.

B. Lämmle, J. K. Kremer Hovinga, 2012, Hematology. American Society of Hematology. Education Program.

Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura

S. Vesely, J. George, B. Lämmle, 2009, Transfusion.

Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease

J. George, B. Lämmle, J. K. Kremer Hovinga, 2008, Haematologica.

Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature.

B. Lämmle, M. Gregor, J. K. Kremer Hovinga, 2007, Swiss medical weekly.

Thrombotic thrombocytopenic purpura: advances in pathophysiology, diagnosis, and treatment--introduction.

J. George, B. Lämmle, 2004, Seminars in hematology.

Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency.

B. Lämmle, L. Alberio, J. K. Kremer Hovinga, 2004, Seminars in hematology.

von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience.

B. Lämmle, L. Alberio, J. K. Kremer Hovinga, 2004, Seminars in hematology.

Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura.

B. Lämmle, L. Alberio, A. Tobler, 2004, Haematologica.

Von Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies: diagnostic experience 2001/2002 of a single research laboratory.

B. Lämmle, L. Alberio, J. K. Kremer Hovinga, 2003, Swiss medical weekly.

New strategies in diagnosis and treatment of thrombotic thrombocytopenic purpura: case report and review

B. Lämmle, J. Häberle, H. Jürgens, 1999, European Journal of Pediatrics.

Factor XII clotting activity and antigen levels in patients with thromboembolic disease

B. Lämmle, R. von Känel, W. Wuillemin, 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

purpura Survival and relapse in patients with thrombotic thrombocytopenic

S. Vesely, B. Lämmle, Deirdra R. Terrell, 2011 .

16 Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura

B. Lämmle, M. Furlan, 1998 .

Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura.

B. Lämmle, M. Furlan, 1998, Bailliere's clinical haematology.

Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura.

B. Lämmle, M. Furlan, R. Robles, 1997, Blood.

Prospective cross-sectional study of haemostatic factors in patients with and without coronary artery disease.

B. Lämmle, W. Wuillemin, F. D. Biasiutti, 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Malondialdehyde formation by blood platelets: a diagnostic test to assess acetylsalicylic acid induced thrombocytopathy?

B. Lämmle, M. Furlan, J. Hovinga, 1990, Thrombosis research.

Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency

S. Vesely, J. George, B. Lämmle, 2011, Transfusion.

Subcutaneous low-molecular-weight heparin for treatment of Trousseau’s syndrome

B. Lämmle, W. Wuillemin, M. Furlan, 1997, Annals of Hematology.

thrombotic thrombocytopenic purpura thrombocytopenic disorders: a severely deficient activity is specific for cleaving protease (ADAMTS13) in - Von Willebrand factor

B. Lämmle, L. Alberio, V. Bianchi, 2013 .

Measurement of von Willebrand factor‐cleaving protease (ADAMTS‐13) activity in plasma: a multicenter comparison of different assay methods

B. Lämmle, K. Váradi, U. Budde, 2003, Journal of thrombosis and haemostasis : JTH.

Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura.

B. Lämmle, L. Alberio, V. Bianchi, 2002, Blood.

Qualitative platelet defect and thrombohaemorrhagic complications in a patient with polycythaemia vera

B. Lämmle, L. Alberio, D. Friess, 2003, Hämostaseologie.

Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor‐cleaving protease

B. Lämmle, H. Gerritsen, M. Furlan, 2001, British journal of haematology.

Fibrinogen Milano XIII (Aα 19 Arg→Gly)

B. Lämmle, P. Bucciarelli, M. Furlan, 1999 .

Protein Z in healthy human individuals and in patients with a bleeding tendency

B. Lämmle, W. Wuillemin, T. Mauron, 1998, British journal of haematology.

Fibrinogen Claro--another dysfunctional fibrinogen variant with gamma 275 arginine-->histidine substitution.

B. Lämmle, M. Furlan, E. Beck, 1996, Thrombosis research.

How high is the true fibrinogen content of fibrinogen standards?

B. Lämmle, M. Furlan, N. Escher, 1989, Thrombosis research.

Plasma prekallikrein, factor XII, antithrombin III, C1(-)-inhibitor and alpha 2-macroglobulin in critically ill patients with suspected disseminated intravascular coagulation (DIC).

B. Lämmle, R. Ritz, F. Duckert, 1984, American journal of clinical pathology.

Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura

S. Vesely, J. George, B. Lämmle, 2012, Haematologica.

Prekallikrein deficiency: the characteristic normalization of the severely prolonged aPTT following increased preincubation time is due to autoactivation of factor XII.

B. Lämmle, L. Asmis, M. Furlan, 2002, Thrombosis research.

A quantitative dot immunobinding assay for coagulation factor XII in plasma.

B. Lämmle, W. Wuillemin, M. Furlan, 1990, Journal of immunological methods.

Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies.

B. Lämmle, J. Griffin, H. Schwarz, 1986, Blood.

Patent ductus arteriosus generates neonatal hemolytic jaundice with thrombocytopenia in Upshaw-Schulman syndrome.

B. Lämmle, T. Miyata, K. Kokame, 2019, Blood advances.

Von Willebrand Factor in Thrombotic Thrombocytopenic Purpura

B. Lämmle, M. Furlan, 1999, Thrombosis and Haemostasis.

Progressive multifocal leukoencephalopathy in common variable immunodeficiency: mitigated course under mirtazapine and mefloquine

B. Lämmle, R. Wiest, C. Bassetti, 2015, Journal of NeuroVirology.

Biocompatibility in transfusion medicine.

B. Lämmle, R. Rieben, U. Nydegger, 1996, Transfusion science.

Biological individuality and the new frontiers of immunological tolerance in hematopoietic stem cell transplantation

S. Vesely, J. George, B. Lämmle, 2010 .

Diagnostic Criteria for Hematopoietic Stem Cell Transplantation-Associated Microangiopathy (TAM): Results of a Consensus Process by an International Working Group.

J. Moake, J. George, B. Lämmle, 2005 .

Acquired deficiency of von Willebrand factor-cleaving protease in a patient suffering from acute systemic lupus erythematosus.

B. Lämmle, T. Güngör, R. Seger, 2001, Rheumatology.

Immunogenic hotspots in the spacer domain of ADAMTS13 in immune‐mediated thrombotic thrombocytopenic purpura

B. Lämmle, H. Rossmann, J. Voorberg, 2020, Journal of thrombosis and haemostasis : JTH.

Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura.

B. Lämmle, H. Rossmann, J. Voorberg, 2020, Blood.

Thrombotic thrombocytopenic purpura and pregnancy

B. Lämmle, C. Auer, J. Hovinga, 2016 .

VWF and complement.

B. Lämmle, 2015, Blood.

Current insights into thrombotic microangiopathies: Thrombotic thrombocytopenic purpura and pregnancy.

B. Lämmle, J. K. Kremer Hovinga, A. von Krogh, 2015, Thrombosis research.

hemoglobin ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by Fatal congenital thrombotic thrombocytopenic purpura with apparent

B. Lämmle, M. Hermann, F. Scheiflinger, 2013 .

Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports.

S. Vesely, J. George, B. Lämmle, 2007, Haematologica.

ADAMTS13 activity in sickle cell disease

B. Lämmle, A. Duits, S. Akin, 2006, American journal of hematology.

Measurement of ADAMTS‐13 activity in plasma by the FRETS‐VWF73 assay: comparison with other assay methods

B. Lämmle, J. K. Kremer Hovinga, M. Mottini, 2006, Journal of thrombosis and haemostasis : JTH.

A new tool to further explore the role of ADAMTS‐13 in health and disease

B. Lämmle, J. K. Kremer Hovinga, 2006, Journal of thrombosis and haemostasis : JTH.

Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin.

B. Lämmle, M. Hermann, J. K. Kremer Hovinga, 2005, Blood.

Discrepant activity levels of von Willebrand factor-cleaving protease (ADAMTS-13) in congenital thrombotic thrombocytopenic purpura.

B. Lämmle, J. K. Kremer Hovinga, J. Studt, 2003, Blood.

Ten years of prophylactic treatment with fresh‐frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor‐cleaving protease

B. Lämmle, E. Costa, M. Guerra, 2001, British journal of haematology.

Haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura--new insights into underlying biochemical mechanisms.

B. Lämmle, M. Furlan, 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Splenectomy in thrombotic thrombocytopenic purpura

B. Lämmle, M. Furlan, 2000, American journal of hematology.

Von Willebrand Factor-cleaving Protease in Childhood Diarrhoea-associated Haemolytic Uraemic Syndrome

B. Lämmle, G. Haycock, B. Hunt, 2001, Thrombosis and Haemostasis.

Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers.

B. Lämmle, D. Meyer, M. Furlan, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura.

S. Vesely, J. George, B. Lämmle, 2014, Blood.

Congratulations to Toshiyuki Miyata, PhD

B. Lämmle, 2022, Japanese Journal of Thrombosis and Hemostasis.

Assessing thrombogenesis and treatment response in congenital thrombotic thrombocytopenic purpura

B. Lämmle, R. Liesner, M. Scully, 2021, EJHaem.

Diagnosis of Hereditary TTP Caused by Homozygosity for a Rare Complex ADAMTS13 Allele After Salmonella Infection in a 43-Year-Old Asylum Seeker

B. Lämmle, H. Rossmann, R. Wendt, 2021, Frontiers in Medicine.

The impact of congenital thrombotic thrombocytopenic purpura on pregnancy complications

B. Lämmle, A. Waage, G. Tjønnfjord, 2014, Thrombosis and Haemostasis.

A first case of congenital TTP on the African continent due to a new homozygous mutation in the catalytic domain of ADAMTS13

B. Lämmle, B. Meddeb, E. Gouider, 2008, Annals of Hematology.

Assays of von Willebrand Factor- Cleaving Protease: A Test for Diagnosis of Familial and Acquired Thrombotic Thrombocytopenic Purpura

B. Lämmle, M. Furlan, 2002, Seminars in thrombosis and hemostasis.

Characterization of Five Homozygous ADAMTS13 Mutations in Hereditary Thrombotic Thrombocytopenic Purpura – Towards a Phenotype-Genotype Correlation?

B. Lämmle, S. Meyer, X. Zheng, 2008 .

A common origin of the 4143insA ADAMTS13 mutation

B. Lämmle, T. Wienker, T. Becker, 2006, Thrombosis and Haemostasis.

Purified Human Plasma Kallikrein Does Not Stimulate but Primes Neutrophils for Superoxide Production

B. Lämmle, W. Zimmerli, B. Bouma, 1989, Thrombosis and Haemostasis.

Hemophilia A Pseudoaneurysm in a Patient with High Responding Inhibitors Complicating Total Knee Arthroplasty: Embolization: A Cost-Reducing Alternative to Medical Therapy

B. Lämmle, S. Eggli, R. Kickuth, 2006, CardioVascular and Interventional Radiology.

Different Assessment of Plasmin with Different Substrates

B. Lämmle, F. Duckert, C. Bondeli, 1980, Thrombosis and Haemostasis.

Factor XIII in severe sepsis and septic shock.

B. Lämmle, C. Hack, V. Schroeder, 2007, Thrombosis research.

AUTOACTIVATION OF HUMAN PLASMA PREKALLIKREIN

J Rosing, B. Lämmle, J. Griffin, 1987, Thrombosis and Haemostasis.

Functional characterization of an abnormal factor XII molecule (F XII Bern).

B. Lämmle, W. Wuillemin, M. Furlan, 1991, Blood.

Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic‐uremic syndromes

S. Vesely, J. George, B. Lämmle, 2010, American journal of hematology.

Heparin-dependent in vitro aggregation of normal platelets by plasma of a patient with heparin-induced skin necrosis: specific diagnostic test for a rare side effect.

B. Lämmle, H. Stricker, M. Furlan, 1988, The American journal of medicine.

Binding of calcium ions and their effect on clotting of fibrinogen Milano III, a variant with truncated Aα‐chains

B. Lämmle, M. Furlan, C. Steinmann, 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Concomitant treatment with lamivudine renders cladribine inactive by inhibition of its phosphorylation

B. Lämmle, H. Chtioui, B. Lauterburg, 2009, British journal of haematology.

Circulating extracellular DNA is an independent predictor of mortality in elderly patients with venous thromboembolism

B. Lämmle, T. Renné, D. Aujesky, 2018, PloS one.

Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group.

J. Moake, J. George, B. Lämmle, 2007, Haematologica.

Chronic interstitial nephritis in Whipple's disease

B. Lämmle, F. Gudat, J. Torhorst, 1983, Klinische Wochenschrift.

Normal Binding of Calcium to Five Fibrinogen Variants with Mutations in the Carboxy Terminal Part of the γ-Chain

B. Lämmle, M. Furlan, B. Stucki, 1996, Thrombosis and Haemostasis.

Platelet Aggregation, β-Thromboglobulin and Platelet Factor 4 in Diabetes Mellitus and in Patients with Vasculopathy

B. Lämmle, J. Fritschi, W. Berger, 1984, Thrombosis and Haemostasis.

Fifteen Coagulation and Fibrinolysis Parameters in Diabetes Mellitus and in Patients with Vasculopathy

B. Lämmle, J. Fritschi, W. Berger, 1984, Thrombosis and Haemostasis.

Cold Promoted Activation and Factor XII, Prekallikrein and C1-Inhibitor

B. Lämmle, C. Czendlik, F. Ducket, 1985, Thrombosis and Haemostasis.

Fibrinogen St. Gallen I (γ 292 Gly → Val): Evidence for Structural Alterations Causing Defective Polymerization and Fibrinogenolysis

B. Lämmle, A. Haeberli, M. Furlan, 1999, Thrombosis and Haemostasis.

A new substitution, gamma 358 Ser-->Cys, in fibrinogen Milano VII causes defective fibrin polymerization.

B. Lämmle, M. Furlan, R. Redaelli, 1994, Blood.

Fibrinogen Milano V: a congenital dysfibrinogenaemia with a gamma 275 Arg-->Cys substitution.

B. Lämmle, M. Furlan, R. Redaelli, 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Fibrinogen Bern I: substitution gamma 337 Asn-->Lys is responsible for defective fibrin monomer polymerization

B. Lämmle, M. Furlan, G. Heinemann, 1993 .

The Contact Phase of Blood Coagulation in Diabetes Mellitus and in Patients with Vasculopathy

B. Lämmle, J. Fritschi, W. Berger, 1984, Thrombosis and Haemostasis.

Contact system activation in human sepsis - 47kD HK, a marker of sepsis severity?

B. Lämmle, L. Asmis, R. Asmis, 2008, Swiss medical weekly.

Factor XII, Plasma Prekallikrein, α2-Macroglobulin and C1-Inhibitor Levels in Renal Allograft Recipients During Immunosuppression with Cyclosporin A – Sequential Measurements over Four Months in 17 Patients

B. Lämmle, M. Oberholzer, A. Lohri, 1987, Thrombosis and Haemostasis.

Inferior vena cava thrombosis in a child with nephroblastoma and combined deficiency of antithrombin III and free protein S

B. Lämmle, A. Hirt, M. Furlan, 1990, Blut.

Functional Characterization of a Variant Prekallikrein (PK Zürich)

B. Lämmle, W. Wuillemin, M. Furlan, 1993, Thrombosis and Haemostasis.

Functional Characterization of a Variant Factor XII (F XII Locarno) in a Cross Reacting Material Positive F XII Deficient Plasma

B. Lämmle, H. Stricker, W. Wuillemin, 1992, Thrombosis and Haemostasis.

Purified Factor XII Has a Higher Specific Activity than the Parent Molecule in Plasma

B. Lämmle, W. Wuillemin, M. Furlan, 1991, Thrombosis and Haemostasis.

High Molecular Weight Kininogen Is Cleaved by FXIa at Three Sites: Arg⁴⁰⁹ -Arg⁴¹⁰ , Lys⁵⁰² -Thr⁵⁰³ and Lys³²⁵ -Lys³²⁶

B. Lämmle, W. Wuillemin, T. Mauron, 2017 .

C1-inhibitor in patients with severe sepsis and septic shock: Beneficial effect on renal dysfunction

B. Lämmle, C. Hack, R. Rieben, 2002, Critical care medicine.

Amidolytic activity in normal human plasma assessed with chromogenic substrates.

B. Lämmle, R. Eichlisberger, G. Marbet, 1979, Thrombosis research.

Plasma prekallikrein determination.

B. Lämmle, F. Duckert, 1982, The New England journal of medicine.

Detection and Quantitation of Cleaved and Uncleaved High Molecular Weight Kininogen in Plasma by Ligand Blotting with Radiolabeled Plasma Prekallikrein or Factor XI

B. Lämmle, J. Griffin, J. Curd, 1988, Thrombosis and Haemostasis.

Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease.

B. Lämmle, B. Binder, W. Wuillemin, 2002, Atherosclerosis.

The Amidolytic Prekallikrein (PK) Determination: Enhanced PK Activation After Deep-Freezing of Patients' Plasmas

B. Lämmle, T. Tran, 1983, Thrombosis and Haemostasis.

Monitoring of Oral Anticoagulation by an Amidolytic Factor X Assay

B. Lämmle, H. Bounameaux, R. Eichlisberger, 1980, Thrombosis and Haemostasis.

Plasmin Inhibitors and Fibrinogen Breakdown During the Initial Phase of Thrombolytic Treatment - The Problem of the α2-Antiplasmin Determination

B. Lämmle, G. Noll, F. Duckert, 1984, Thrombosis and Haemostasis.

Thrombotic Risk of Women with Hereditary Antithrombin III-, Protein C- and Protein S-Deficiency Taking Oral Contraceptive Medication

B. Lämmle, A. Gabelmann, S. Eichinger, 1994, Thrombosis and Haemostasis.

Reevaluation of the Incidence of Thromboembolic Complications in Congenital Factor XII Deficiency

B. Lämmle, W. Engel, S. Zeerleder, 1999, Thrombosis and Haemostasis.

[Control of oral anticoagulation: comparison between Quick and colorimetric factor X determination in 107 patients].

B. Lämmle, H. Bounameaux, R. Eichlisberger, 1979, Schweizerische medizinische Wochenschrift.

[Hemostasis parameters in 55 patients with venous and/or arterial thromboembolisms].

B. Lämmle, M. Furlan, I. Sulzer, 1989, Schweizerische medizinische Wochenschrift.

[Evaluating the origin of thrombophilia: indications and implementation].

B. Lämmle, F. Demarmels Biasiutti, 1992, Therapeutische Umschau. Revue therapeutique.

Quantitative Immunoblotting of Plasma and Platelet Protein S

B. Lämmle, J. Griffin, H. Schwarz, 1986, Thrombosis and Haemostasis.

Quantitative immunoblotting assay of blood coagulation factor XII.

B. Lämmle, J. Griffin, H. Schwarz, 1986, Thrombosis research.

Assay of Factor XII clotting activity in heparinized plasma.

B. Lämmle, F. Duckert, T. Tran, 1983, American journal of clinical pathology.

Heparin Cofactor II: Purification and Antibody Production

B. Lämmle, F. Duckert, T. Tran, 1986, Thrombosis and Haemostasis.

Treatment with stanozolol before thrombolysis in patients with arterial occlusions.

B. Lämmle, G. Noll, F. Duckert, 1985, Thrombosis research.

Protein Z in ischaemic stroke

B. Lämmle, H. Mattle, W. Wuillemin, 2001, British journal of haematology.

Frequency of protein Z deficiency in patients with ischaemic stroke

B. Lämmle, H. Mattle, W. Wuillemin, 2001, The Lancet.

Hemostatic risk factors in ischemic stroke Franziska

B. Lämmle, H. Mattle, W. Wuillemin, 2018 .

Screening for lupus anticoagulant: improving the performance of the lupus‐sensitive PTT‐LA

B. Lämmle, R. Luginbühl, I. Sulzer, 2011, International journal of laboratory hematology.

Improved detection of proteolytically cleaved high molecular weight kininogen by immunoblotting using an antiserum against its reduced 47 kDa light chain

B. Lämmle, M. Furlan, I. Aebi-Huber, 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Severe plasma prekallikrein deficiency: Clinical characteristics, novel KLKB1 mutations, and estimated prevalence

B. Lämmle, K. Lackner, H. Rossmann, 2020, Journal of thrombosis and haemostasis : JTH.

Thromboembolism and Bleeding Tendency in Congenital Factor XII DeficienCy - A Study on 74 Subjects from 14 Swiss Families

B. Lämmle, W. Wuillemin, M. Furlan, 1991, Thrombosis and Haemostasis.

Mutations in the human factor XII gene.

B. Lämmle, W. Engel, S. Zeerleder, 1997, Blood.

c.451dupT in KLKB1 is common in Nigerians, confirming a higher prevalence of severe prekallikrein deficiency in Africans compared to Europeans

B. Lämmle, P. Wild, K. Lackner, 2020, Journal of thrombosis and haemostasis : JTH.

Immunoblotting studies of coagulation factor XII, plasma prekallikrein, and high molecular weight kininogen.

B. Lämmle, J. Griffin, M. Berrettini, 1987, Seminars in thrombosis and hemostasis.

Amidolytic Prekallikrein (PK) Assay: Unsuitability of Cephotest® as an Activator

B. Lämmle, A. Lohri, T. Tran, 1984, Thrombosis and Haemostasis.

Influence of Low Molecular Weight Heparin and Low Molecular Weight Dextran Sulfate on the Inhibition of Coagulation Factor XIa by Serpins

B. Lämmle, W. Wuillemin, T. Mauron, 1998, Thrombosis and Haemostasis.

Comments on 'Quantification of human high molecular weight kininogen by immunoblotting with a monoclonal anti-light chain antibody' by Reddigari and Kaplan.

B. Lämmle, 1989, Journal of immunological methods.

Effective therapy with tranexamic acid in a case of chronic disseminated intravascular coagulation with acquired α2-antiplasmin deficiency associated with AL amyloidosis

B. Lämmle, L. Alberio, G. Colucci, 2009, Thrombosis and Haemostasis.

High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence

B. Lämmle, C. Largiadèr, A. Waage, 2016, Journal of thrombosis and haemostasis : JTH.

ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.

S. Vesely, J. George, B. Lämmle, 2003, Blood.

Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura.

Miha Furlan, B. Lämmle, L. Alberio, 2002, Blood.

Thrombotic thrombocytopenic purpura

Karen Vanhoorelbeke, Paul Coppo, J. Moake, 2017, Nature Reviews Disease Primers.

Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies

P. Coppo, B. Lämmle, K. Friedman, 2017, Journal of thrombosis and haemostasis : JTH.

Survival and relapse in patients with thrombotic thrombocytopenic purpura.

S. Vesely, J. George, B. Lämmle, 2010, Blood.

The novel acceptor splice site mutation 11396(G-->A) in the factor XII gene causes a truncated transcript in cross-reacting material negative patients.

B. Lämmle, W. Engel, S. Hofferbert, 1995, Human molecular genetics.

Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer.

S. Vesely, J. George, B. Lämmle, 2012, Presse medicale.

Acquired von Willebrand syndrome in myeloproliferative disorder

B. Lämmle, L. Alberio, P. Baud, 2003, Hämostaseologie.

Elevated nucleosome levels in systemic inflammation and sepsis*

B. Lämmle, C. Hack, A. van Nieuwenhuijze, 2003, Critical care medicine.

in a prospective cohort of 142 patients uremic syndrome: relation to presenting features and clinical outcomes hemolytic - ADAMTS13 activity in thrombotic thrombocytopenic purpura

S. Vesely, J. George, B. Lämmle, 2013 .

Thrombotic thrombocytopenic purpura.

B. Lämmle, L. Alberio, J. K. Kremer Hovinga, 2005, Journal of thrombosis and haemostasis : JTH.

Ribosomal and Immune Transcripts Associate with Relapse in Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura

S. Vesely, J. George, B. Lämmle, 2015, PloS one.

Warning: Simplate II -Lack of Standardization in Standardized Bleeding Time Devices

B. Lämmle, M. Furlan, I. Sulzer, 1990, Thrombosis and Haemostasis.

Fibrinogens Bern IV, Bern V and Milano XI: three dysfunctional variants with amino acid substitutions in the thrombin cleavage site of the Aalpha-chain.

B. Lämmle, M. Furlan, R. Redaelli, 1999, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

A frameshift mutation in Exon V of the A alpha-chain gene leading to truncated A alpha-chains in the homozygous dysfibrinogen Milano III.

B. Lämmle, M. Furlan, R. Redaelli, 1994, The Journal of biological chemistry.

Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients

B. Lämmle, L. Alberio, I. Sulzer, 2012, Haematologica.

The Swiss cohort of elderly patients with venous thromboembolism (SWITCO65+): rationale and methodology

B. Lämmle, M. Aschwanden, J. Cornuz, 2013, Journal of Thrombosis and Thrombolysis.

The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs.

B. Lämmle, M. Vogel, J. K. Kremer Hovinga, 2014, Blood.

D-Dimers Predict Stroke Subtype when Assessed Early

B. Lämmle, L. Alberio, N. Meier, 2009, Cerebrovascular Diseases.

Is factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS13 deficiency?

B. Lämmle, J. Studt, I. Sulzer, 2005, Thrombosis and Haemostasis.

Thromboembolism in patients with congenital afibrinogenaemia

B. Lämmle, L. Alberio, H. von Tengg-Kobligk, 2016, Thrombosis and Haemostasis.

Hemostatic risk factors in ischemic stroke

B. Lämmle, H. Mattle, W. Wuillemin, 2003, Thrombosis and Haemostasis.

In Vitro Effects of the Acylated StreptokinasePlasminogen Activator Complex BRL 33 575 Incubated with Normal Human Plasma

B. Lämmle, G. Noll, A. Lohri, 1984, Thrombosis and Haemostasis.

Depressive Symptoms as a Novel Risk Factor for Recurrent Venous Thromboembolism: A Longitudinal Observational Study in Patients Referred for Thrombophilia Investigation

B. Lämmle, R. von Känel, S. Stauber, 2015, PloS one.

Cognitive deficits after recovery from thrombotic thrombocytopenic purpura

James G. Scott, S. Vesely, J. George, 2009, Transfusion.

Predictors and Outcomes of Recurrent Venous Thromboembolism in Elderly Patients.

B. Lämmle, M. Aschwanden, J. Cornuz, 2018, The American journal of medicine.

Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura.

S. Vesely, J. George, B. Lämmle, 2013, Blood.

Derivation and validation of a novel bleeding risk score for elderly patients with venous thromboembolism on extended anticoagulation

B. Lämmle, M. Aschwanden, N. Rodondi, 2017, Thrombosis and Haemostasis.

Predictors and Causes of Long-Term Mortality in Elderly Patients with Acute Venous Thromboembolism: A Prospective Cohort Study.

B. Lämmle, M. Aschwanden, J. Cornuz, 2017, The American journal of medicine.

Thrombophilia and outcomes of venous thromboembolism in older patients

B. Lämmle, L. Alberio, N. Rodondi, 2022, Research and practice in thrombosis and haemostasis.

Risk stratification of elderly patients with acute pulmonary embolism

B. Lämmle, M. Aschwanden, N. Rodondi, 2019, European journal of clinical investigation.

The effects of intravenous iron supplementation on fatigue and general health in non-anemic blood donors with iron deficiency: a randomized placebo-controlled superiority trial

B. Lämmle, C. Hincapié, R. von Känel, 2020, Scientific Reports.

ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases.

B. Lämmle, G. Remuzzi, P. Mannucci, 2005, Blood.

THROMBOSIS AND HEMOSTASIS The splenic autoimmune response to ADAMTS 13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR 3 motifs

B. Lämmle, M. Vogel, M. Schaller, 2014 .

Genetic Predisposition to Bleeding during Oral Anticoagulant Therapy: Evidence for Common Founder Mutations (FIXVal-10 and FIXThr-10) and an Independent CpG Hotspot Mutation (FIXThr-10)

B. Lämmle, J. Oldenburg, B. Konkle, 2001, Thrombosis and Haemostasis.

Founder Effect of the Factor-IX-Propeptide-Val-10 Variant Is Responsible for Most Marcumar-lnduced Severe Haemophilia B Cases During Oral Anticoagulant Therapy — Consequences for Monitoring

B. Lämmle, J. Oldenburg, V. Ivaškevičius, 1999 .

[Unexpectedly prolonged thrombin time].

B. Lämmle, M. Furlan, A. Barth, 1993, Swiss medical weekly.

Factor VIII (procoagulant activity VIII:C, and antigen VIII:CAg, related antigen VIIIR:Ag and ristocetin cofactor VIIIR:Cof) in intensive care patients with clinically suspected disseminated intravascular coagulation (DIC).

B. Lämmle, F. Duckert, T. Tran, 1984, American Journal of Clinical Pathology.

Variability of anti‐PF4/heparin antibody results obtained by the rapid testing system ID‐H/PF4‐PaGIA

B. Lämmle, L. Alberio, G. Colucci, 2009, Journal of thrombosis and haemostasis : JTH.

ADAMTS‐13, von Willebrand factor and related parameters in severe sepsis and septic shock

B. Lämmle, P. Reitsma, C. Hack, 2007, Journal of thrombosis and haemostasis : JTH.

Images in clinical medicine. Capnocytophaga canimorsus sepsis.

B. Lämmle, L. Alberio, 2009, The New England journal of medicine.

Variability of anti‐PF4/heparin antibody results obtained by the rapid testing system ID‐H/PF4‐PaGIA: reply to a rebuttal

B. Lämmle, L. Alberio, G. Colucci, 2009 .

International Registry for Patients with Hereditary Thrombotic Thrombocytopenic Purpura (TTP) – Upshaw-Schulman Syndrome

J. George, B. Lämmle, Y. Fujimura, 2012 .

The Frequency of Rheumatic Disease Autoantibodies in Patients with ADAMTS13-Deficient Thrombotic Thrombocytopenia Purpura (TTP).

S. Vesely, J. George, B. Lämmle, 2007 .

Opana ER-induced thrombotic microangiopathy.

B. Lämmle, 2017, Blood.

Progressive multifocal leukoencephalopathy in common variable immunodeficiency: mitigated course under mirtazapine and mefloquine

B. Lämmle, R. Wiest, C. Bassetti, 2015, Journal of NeuroVirology.

Impaired DNase1‐mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies

B. Lämmle, T. Renné, H. Mannherz, 2015, Journal of thrombosis and haemostasis : JTH.

Apoptosis In Sepsis And Multiple Organ Dysfunction Syndrome

B. Lämmle, C. Hack, A. Groeneveld, 2004 .

In vitro rescue of FGA deletion by lentiviral transduction of an afibrinogenemic patient's hepatocytes

B. Lämmle, D. Candinas, A. Fort, 2014, Journal of thrombosis and haemostasis : JTH.

IFNα treatment in systemic mastocytosis

B. Lämmle, T. Lehmann, 1999, Annals of Hematology.

1,25 (OH)2 Vitamin D3 in Osteoporosis - A Pilot Study* **

B. Lämmle, M. Dambacher, T. Lauffenburger, 1979, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Is Plasminogen Deficiency a Thrombotic Risk Factor ? – A Study on 23 Thrombophilic Patients and their Family Members

B. Lämmle, W. Wuillemin, M. Furlan, 1998, Thrombosis and Haemostasis.

[Severe hemorrhage, lymphocytosis and leukoerythroblastic blood picture--disseminated intravascular coagulation in metastatic prostate carcinoma and chronic lymphatic leukemia].

B. Lämmle, M. Solenthaler, 1999, Therapeutische Umschau. Revue thérapeutique.

SimpliRED D-dimer Assay: Comparability of Capillary and Citrated Venous Whole Blood, Between-assay Variability, and Performance of the Test for Exclusion of Deep Vein Thrombosis in Symptomatic Outpatients

B. Lämmle, I. Baumgartner, B Lämmle, 1998, Thrombosis and Haemostasis.

No association of APC resistance with myocardial infarction.

B. Lämmle, B. Binder, M. Furlan, 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Binding of alpha-thrombin to fibrin depends on the quality of the fibrin network.

B. Lämmle, M. Furlan, H. Bänninger, 1994, The Biochemical journal.

Endothelial Dysfunction, Atherosclerosis, and Increase of Von Willebrand Factor and Factor VIII: A Randomized Controlled Trial in Swine

B. Lämmle, 2021, Thrombosis and Haemostasis.

[Acute hyperkalemia and non-oliguric kidney failure during treatment with indomethacin, allopurinol, nifedipine, hydrochlorothiazide/amiloride, trimethoprim/sulfamethoxazole and acetylsalicylic acid].

B. Lämmle, K. Blaser, 1988, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis.

High Molecular Weight Kininogen Is Cleaved by FXIa at Three Sites: Arg409-Arg410, Lys502-Thr503 and Lys325-Lys326

B. Lämmle, W. Wuillemin, T. Mauron, 2000, Thrombosis and Haemostasis.

Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis

B. Lämmle, L. Alberio, F. Frey, 2007, Thrombosis and Haemostasis.

Prospective comparison of clinical prognostic scores in elder patients with a pulmonary embolism

B. Lämmle, M. Aschwanden, J. Cornuz, 2012, Journal of thrombosis and haemostasis : JTH.

A third form of thrombotic thrombocytopenic purpura?

B. Lämmle, 2022, Haematologica.

Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura.

B. Lämmle, H. Rossmann, J. Voorberg, 2021, Blood advances.

Neurocognitive Impairment Following Recovery from ADAMTS13-Deficient Thrombotic Thrombocytopenia Purpura (TTP).

James G. Scott, S. Vesely, J. George, 2007 .

Sporadic Bloody Diarrhea-Associated Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) in Adults in Oklahoma: Comparison to Adults with Severe Adamts13 Deficiency and to Children with Typical HUS.

S. Vesely, J. George, B. Lämmle, 2007 .

Predicting Risk for Relapse in Patients Who Have Recovered from Thrombotic Thrombocytopenic Purpura (TTP).

S. Vesely, J. George, B. Lämmle, 2006 .

On the dosing of lepirudin.

B. Lämmle, L. Alberio, 2011, British journal of clinical pharmacology.

Bilateral periorbital ecchymoses

B. Lämmle, L. Alberio, G. Colucci, 2014, Hämostaseologie.

More on: thrombosis and ELISA optical density values in hospitalized patients with heparin‐induced thrombocytopenia

B. Lämmle, L. Alberio, 2005, Journal of thrombosis and haemostasis : JTH.

Decreased Free Protein S Levels in Polycythemia Vera

B. Lämmle, M. Zoppi, W. Wuillemin, 1990, Thrombosis and Haemostasis.

Control of Heparin Treatment with three Different Methods. Behaviour of Antithrombin III

B. Lämmle, H. Bounameaux, R. Eichlisberger, 1979, Thrombosis and Haemostasis.

Massive muscle haematoma three months after starting vitamin K antagonist therapy for deep-vein thrombosis in an antithrombin deficient patient: Another case of factor IX propeptide mutation

B. Lämmle, L. Alberio, J. Oldenburg, 2011, Thrombosis and Haemostasis.

Hereditary thrombotic thrombocytopenic purpura and COVID‐19: Impacts of vaccination and infection in this rare disease

J. George, B. Lämmle, K. Friedman, 2022, Research and Practice in Thrombosis and Haemostasis.

von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

B. Lämmle, G. Remuzzi, P. Kyrle, 1998 .

Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry.

J. George, B. Lämmle, P. Knöbl, 2013, Hamostaseologie.

Schistocytic anaemia, severe thrombocytopenia, and renal dysfunction: thrombotic microangiopathy due to severe acquired ADAMTS-13 deficiency

B. Lämmle, A. Winkler, V. Bianchi, 2003, Hämostaseologie.

Late onset and pregnancy-induced congenital thrombotic thrombocytopenic purpura

B. Lämmle, K. Lackner, I. Scharrer, 2014, Hämostaseologie.

Rumpel–Leede sign in thrombocytopenia due to Epstein–Barr virus‐induced mononucleosis

B. Lämmle, G. Mantokoudis, P. Dubach, 2010, British journal of haematology.

Plasminogen Deficiency: An Additional Risk Factor for Thrombosis in a Family with Factor V R506Q Mutation?

B. Lämmle, M. Furlan, F. Demarmels Biasiutti, 1996, Thrombosis and Haemostasis.

Clinical Problem Solving and Using New Paths in the Laboratory: Learning from Case Studies

B. Lämmle, 2020, Hämostaseologie.

Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy: Pathophysiology and Differentiation from Graft versus Host Disease

B. Lämmle, 2019, Thrombosis and Haemostasis.

[Thrombotic thrombocytopenic purpura--an often missed diagnosis].

B. Lämmle, J. K. Kremer Hovinga, M. Adler, 2014, Revue medicale suisse.

Contact phase of blood coagulation is not activated in edema of high altitude.

B. Lämmle, P. Vock, A. Haeberli, 1989, Journal of applied physiology.

Mechanisms of ADAMTS13 inhibition in iTTP.

B. Lämmle, 2023, Blood.

Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature

B. Lämmle, L. Alberio, I. Sulzer, 2008, Thrombosis and Haemostasis.

A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura

B. Lämmle, K. Lackner, H. Rossmann, 2023, Blood advances.

Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies.

B. Lämmle, D. Wagner, T. Fuchs, 2012, Blood.

Major coagulation disorders when using aprotinin--observations on a case.

B. Lämmle, P. Schüpbach, U. Althaus, 1991, The thoracic and cardiovascular surgeon.

Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency

S. Vesely, J. George, B. Lämmle, 2011, Transfusion.

Reply to Rebuttal: von Willebrand Factor-cleaving Protease in Childhood Diarrhoea-associated Haemolytic Uraemic Syndrome

B. Lämmle, G. Haycock, B. Hunt, 2002, Thrombosis and Haemostasis.

Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins.

B. Lämmle, J. K. Kremer Hovinga, C. Dahinden, 2004, Blood.

May-Thurner syndrome: missed diagnosis and missed early treatment?

B. Lämmle, A. Trinchero, S. Schotten, 2017, Hämostaseologie.

Influence of Personality, Resilience and Life Conditions on Depression and Anxiety in 104 Patients Having Survived Acute Autoimmune Thrombotic Thrombocytopenic Purpura

B. Lämmle, M. Beutel, K. Lackner, 2021, Journal of clinical medicine.

[Patient self-monitoring of oral anticoagulation with CoaguChek].

B. Lämmle, H. Saner, W. Wuillemin, 2000, Schweizerische medizinische Wochenschrift.